Venous stenting has evolved over the last 15 years, quickly becoming an established procedure, with Class II recommendations from the American Heart Association and American College of Phlebology. Speaking at the Vascular Society of Great Britain and Ireland’s Annual Scientific Meeting (VSGBI; 22–24 November 2017, Manchester, UK), Ankur Thapar presented results from the Venous Research Unit at Imperial College (London, UK) reviewing an expert consensus on antithrombotic therapy following venous stenting.
Global healthcare company Penumbra has entered into a joint venture with virtual reality (VR) company Sixense Enterprises, for the purpose of exploring healthcare applications of the technology.
Endovascular navigation startup Centerline Biomedical has successfully completed a fifth preclinical study at Cleveland Clinic facilities evaluating its surgical navigation system, the Intra-Operative Positioning System (IOPS). The study was the company’s most noteworthy study to date; demonstrating ability to track sensorised IOPS instruments precisely and efficiently with enhanced three-dimensional (3D) visualisation and without frequent exposure to cancer-causing ionising radiation associated with current standard of care.
The first patients have been enrolled in the US FDA pivotal study of VasQ (Laminate Medical Technologies), an implanted blood vessel external support device for patients requiring arteriovenous fistula as vascular access for haemodialysis.
Bluegrass Vascular Technologies has announced the enrolment of its first patients in the SAVE-US (Surfacer System to Facilitate Access in Venous Occlusions–United States) pivotal trial.
Dosimetry, within the context of selective internal radiation therapy (SIRT) using Y-90 microspheres, is typically understood to be the measurement and calculation of the absorbed dose in matter and tissue resulting from the exposure to indirect and direct ionising radiation.
A prospective randomised controlled study that compared outcomes between hepatocellular carcinoma patients who were treated by microwave ablation with those who were treated by radiofrequency ablation, did not find a benefit for microwave over radiofrequency.
Researchers from the University College London (UCL) Cancer Institute, London, UK, and BTG have begun the first clinical trial of an experimental treatment for liver cancer using X-ray imageable microscopic beads loaded with a targeted anti-cancer drug placed directly in the liver.
“While both radial and femoral accesses are safe and effective for transarterial liver embolization, it is clear that the patients prefer radial access,” said Marcelo Guimaraes, Charleston, USA, who was presenting on the BEST ACCESS trial at the Super Tuesday session during the 2017 CIRSE annual meeting.
The world’s largest randomised trial comparing three central venous access devices—peripherally inserted central catheters (PICCs), Hickman-type devices and chest wall ports—should provide definitive results in terms of their relative efficacy and cost-effectiveness, Jon Moss, Glasgow, UK, told CIRSE delegates.
Guerbet has announced obtaining the CE mark for its conventional transarterial chemoembolization (cTACE) mixing and injection system, Vectorio.
Royal Philips has announced that it has acquired VitalHealth, a provider of cloud-based population health management solutions for the delivery of personalised care outside of the hospital, for example, in regional care networks.
A study of nearly 62,000 hospitalisations nationwide in the USA has found that more than one in six patients with peripheral arterial disease (PAD) who undergo revascularisation procedures to restore blood flow to blocked leg arteries and other arteries outside of the heart are readmitted to the hospital within 30 days.
InspireMD has announced it has signed Diverse Devices as its exclusive distributor for Australia and New Zealand, and has signed Do Gia Production and Trading JSC as its exclusive distributor in Vietnam. The company’s product line includes the Cguard embolic prevention system (EPS).
The majority of patients were pain free after receiving a new image-guided pulsed radiofrequency treatment for low back pain and sciatica, according to a study presented at the annual meeting of the Radiological Society of North America (RSNA; 27 November–1 December, Chicago, USA).
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos